RMR compared with KROS: revenue, margins and what each company keeps, and the suppliers and customers both name

RMRRMR Group Inc.

Mkt capRevenueRevenue

KROSKeros Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

RMRRMR Group Inc.

KROSKeros Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

RMR

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±6.7%▼−0.79%×0.12

Q2 FY26±4.1%▼−1.22%×0.29

Q1 FY26±7.0%▲+7.59%×1.09

Nov 13 '25±8.5%▲+0.51%×0.06

KROS

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±25.5%▲+1.38%×0.05

May 14 '26±32.2%▼−8.34%×0.26

= impliedRMR realized, solidKROS realized, hatchedOne scale, both sides: full bar = 33%× = |realized| ÷ impliedSource: market data

Q1 FY26

±12.0%

▼−14.96%

×1.25

Nov 6 '25±16.3%▲+3.32%×0.20

RMRRMR Group Inc.

16.90▲+1.41%· post 16.76

Mkt cap$534.5MRevenue$154MQ3 FY26Revenue$704MFY25

KROSKeros Therapeutics, Inc.

11.04▲+0.02%· post 10.73

ClosedNov 2 '26

Mkt cap$213.3MRevenue$367,000Q1 FY26Revenue$244MFY25

Compare

ClosedNov 2 '26

RMRRMR Group Inc.

KROSKeros Therapeutics, Inc.

16.90▲+1.41%post 16.76

Price

11.04▲+0.02%post 10.73

$534.5M

Mkt cap

$213.3M

Q3 FY26$154M

Revenue

$367,000Q1 FY26

FY25$704M

Revenue

$244MFY25

RMR16.90▲+1.41%vsKROS11.04▲+0.02%ClosedNov 2 '26